Charpin C, Bonnier P, Devictor B, Andrac L, Lavaut M N, Allasia C, Piana L
Pathology Department, Centre Hospitalier Universitaire Timone, Marseille, France.
Anticancer Res. 1993 May-Jun;13(3):603-12.
The immunodetection of HER-2/neu oncogene product was performed in 108 breast carcinomas using immunoperoxidase technique. Monoclonal anti HER-2/neu protein was applied on frozen sections. Immunoprecipitates were evaluated by a computerized system of image analysis (SAMBA). The percentage of the immunostained tissue surfaces and mean optical densities were correlated with the 5 year overall and disease-free survival rates. It was shown that in optimal conditions of antigen preservation and standardized method of immunoprecipitates evaluation, 67% of breast carcinomas were more than 20% pHER-2/neu positive. The pHER-2/neu overexpression was not significantly correlated with the overall 5 year survival. However large positive anti pHER-2/neu surfaces were correlated with higher risk of recurrence (p = 0.0013) and of metastases (p = 0.035).
采用免疫过氧化物酶技术对108例乳腺癌进行HER-2/neu癌基因产物的免疫检测。将单克隆抗HER-2/neu蛋白应用于冰冻切片。通过图像分析计算机系统（SAMBA）评估免疫沉淀物。免疫染色组织表面的百分比和平均光密度与5年总生存率和无病生存率相关。结果表明，在抗原保存的最佳条件和免疫沉淀物评估的标准化方法下，67%的乳腺癌pHER-2/neu阳性率超过20%。pHER-2/neu过表达与5年总生存率无显著相关性。然而，抗pHER-2/neu大阳性表面与更高的复发风险（p = 0.0013）和转移风险（p = 0.035）相关。
